Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

Analysis of Primary Endpoint for Phase 3 Registration Trial No Later Than

July 2008

SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today reported its financial results for the fourth quarter and year end 2007. For the quarter and year ended December 31, 2007, the Company reported net losses of $7.8 million, or $0.21 per share, and $43.1 million, or $1.28 per share, respectively, compared to $10.2 million, or $0.35 per share, and $40.5 million, or $1.49 per share, for the same periods in 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

"It is with great excitement and anticipation that we begin 2008 and approach the end of our Phase 3 clinical trial of Specifid(TM) (mitumprotimut-T, formerly FavId(R))," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "We are in the process of data collection and are on schedule for data cut off in April and completion of data analysis no later than July. The rate of disease progression continues to be very slow and we believe we have enrolled an optimal patient population to maximize prospects for demonstrating a clinical benefit in our Phase 3 trial."

Fourth Quarter and Year End 2007 Financial Review

Research and development expense was approximately $7.8 million and $34.9 million for the fourth quarter and year ended December 31, 2007, respectively, compared to approximately $7.7 million and $31.1 million for the same periods in 2006. The increase is primarily due to operating expenses, including salaries and stock-based compensation, associated with our commercial-scale manufacturing facility, and consulting and outside services to support our Specifid Phase 3 clinical trial. Total st
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... WISCONSIN (PRWEB) May 29, 2015 Results ... virus talimogene laherparepvec and its ability to reduce the ... treatment have been published in the Journal of Clinical ... patients with stages IIIB, IIIC and IV melanoma, a ... of the study was to evaluate the safety and ...
(Date:5/28/2015)... Research and Markets ... of Jain PharmaBiotech,s new report "Therapeutic ... to their offering.      ... deals with therapeutic drug monitoring, a multi-disciplinary ... by monitoring drug levels in the blood ...
(Date:5/28/2015)... May 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ... Genetics Market by Products, by Testing services - Global ... The global animal genetics market is estimated to ... at a CAGR of 8-9% during the forecast period ... mainly driven by increasing animal protein consumption, increasing adoption ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation (the ... has received commitments from two institutional healthcare investors to ... Company,s common stock in an at-the-market registered direct offering ... common stock. The Company entered into a ... the Company agreed to sell an aggregate of 3,000,000 ...
Breaking Biology Technology:Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Therapeutic Drug Monitoring Market 2015-2024 2Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3
... Shandong Zhouyuan Seed,and Nursery Co., Ltd. (OTC Bulletin ... in the State of Delaware, announced,that its operating ... Co., Ltd. ("Zhouyuan" or "the Company"), had signed ... Yuan Seeds Co., Ltd. ("Kun Yuan") on,August 6, ...
... DVA ) today announced that it will present ... Thursday, September 20, 2007 at 4:15 p.m.,GMT. (Logo: ... go to http://www.ibb.ubs.com, click on the,Conferences icon ... webcast link,listed next to the relevant conference title. The ...
... WCRX ) announced today that LEO Pharma A/S ... U.S. Patent and,Trademark Office (the "USPTO"). In September 2006, ... 6,753,013 (the "013 Patent") in,response to a request made ... of LEO,s products in development. Warner Chilcott markets and,sells ...
Cached Biology Technology:Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company 2Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company 3Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 2Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 3
(Date:5/22/2015)... May 22, 2015 According to ... Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), ... and Utilities, Consumer and Home) - Global Forecast to ... from $2.77 Billion in 2015 to $6.19 Billion by ... Browse 79 market data Tables and   43 Figures ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/19/2015)...  Technology is rapidly advancing, outpacing enterprises, ability to ... Passwords and their management are soon to be rendered ... such as those developed by the FIDO Alliance™. With ... for BYOD, COPE, IoT, and mobile payments, the interconnected ... In response to the call for seamless, ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
... Florida State University study is investigating how quickly the Deepwater ... being degraded by the sands, natural microbial communities, and whether ... helping or hindering that process. What oceanography professors Markus ... predict when most of the oil in the beaches will ...
... NY New research by scientists at Cold Spring Harbor ... genetic paths that leads to a particularly aggressive form of ... an Investigator of the Howard Hughes Medical Institute, led a ... the absence of an important tumor-suppressing protein called p53 combines ...
... A technology meeting energy and climate challenges ... efficient power production. Compared to traditionel technologies SOFCs have a ... 2 . They work by transforming the chemical energy of ... will help meet Danish energy and climate policy goals, and ...
Cached Biology News:How fast can microbes break down oil washed onto Gulf beaches? 2How fast can microbes break down oil washed onto Gulf beaches? 3CSHL team shows how loss of key protein promotes aggressive form of leukemia 2CSHL team shows how loss of key protein promotes aggressive form of leukemia 3
...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Recombinant Mouse sTNF RII/TNFRSF1B...
Biology Products: